

Intellectual Property Rights, And Competition Law
Prof. K D Raju
Rajiv Gandhi School of Intellectual Property Law
Indian Institute of Technology, Kharagpur

Lecture - 22
Vertical Restraints and IP

Dear students, today we are going to continue with our discussion on the last class, we were discussing about the horizontal restraints and today we are going to discuss on Vertical Restraints. In the last classes we have discussed what is the vertical restraints and horizontal restraints. Horizontal restraints are on the same level of trade and vertical restraints are on different level of trade. For example, the distributor, the manufacturer, then retailer, on the same level of trade and if one person tries to control the entire system of supply chain.

In the vertical restraints we are going to look into how the intellectual property interacts with or whether it is conflicting with the competition law in certain cases.

(Refer Slide Time: 01:15)



Especially with regard to the vertical price restraint. Almost all the jurisprudence, cases are on patents or trademarks or copyrights, but this particular case that came before the court is on trade secrets. The distributors or the manufacturer put restraints in the

licensing agreements, contracts, to what extent these are conflicting with the competition law. Today we are going to discuss this in detail, and maybe on the last class of the first part of this course.

(Refer Slide Time: 02:03)



The slide features a light green background with a yellow-to-orange gradient at the bottom. The title 'Vertical price restraint' is centered at the top. Below it, three bullet points are listed. At the bottom left, there are two logos: the Indian Institute of Technology (IIT) logo and the NPTEL logo. A small video inset of a man in a pink shirt is visible on the right side of the slide.

Vertical price restraint

- Dr.Miles – 1911
- Leegin decision – 2007 – reversed the 96 year old precedent.
- **Dr. Miles Medical Co. v. John D. Park & Sons Co., 220 U.S. 373 (1911)**

NPTEL © IIT KGP 2019

And this was very important case but now it is overruled. *Dr. Miles Medical company versus John D. Park and Sons company* was decided in 1911. This case set the jurisprudence for a long period of time, you can see that it got overruled only in 2007.

So, for a long period of time this was the jurisprudence set by the united states of Supreme Court. In 2007 this decision, Dr. Miles decision was overruled in *Leegin decision*. So, our subject of discussion today is these two decision and vertical restraints, and how the intellectual property is interacting with the competition law, the Sherman Act through these two cases.

(Refer Slide Time: 03:07)



Vertical restraints


- A system of contracts between manufacturers and wholesale and retail merchants by which the manufacturers attempt to control not merely the prices at which its agents may sell its products,
- but the prices for all sales by all dealers at wholesale or retail,
- whether purchasers or sub-purchasers,
- eliminating all competition and fixing the amount which the consumer shall pay,
- amounts to restraint of trade,
- and is invalid both at common law and, so far as it affects interstate commerce, under the Sherman Anti-Trust Act of July 2, 1890, and so *held* as to the contracts involved in this case.

The slide features a green and yellow background. At the bottom left, there are logos for an Indian university and NPTEL. At the bottom right, there is a small video inset of a man in a pink shirt speaking.

The vertical restraints are basically on the contracts. The manufactures always enters into contracts with wholesale merchants, retail merchants and tries to control the prices. The prices from manufacturing, to the wholesalers, to the retailers and ultimately to the consumers, and they put restrictions on prices on all levels. So, what is the price of these particular products when available to the consumers? There is no choice for the wholesaler or the retailer to fix prices or to give some kind of leeway; these are entirely fixed by the manufacturers.

So, the question raised in this particular case was whether this amounts to restraint of trade. If this is restraint of trade then it is definitely a violation of the Anti-Trust Act of 1890.

(Refer Slide Time: 04:13)



The slide is titled "Vertical" and contains a bulleted list of facts about Dr. Miles Medical Company. The background is light green with a yellow-to-orange gradient at the bottom. On the bottom left, there are two logos: the Indian Institute of Technology (IIT) logo and the NPTEL logo. On the bottom right, there is a portrait of a man in a light pink shirt. The text is as follows:

Vertical

- The complainant, Dr. Miles Medical Company, an Indiana corporation, is engaged in the manufacture and sale of proprietary medicines,
- prepared by means of secret methods and formulas, and identified by distinctive packages, labels, and trademarks.
- It has established an extensive trade throughout the United States and in certain foreign countries.
- It has been its practice to sell its medicines to jobbers and wholesale druggists, who in turn sell to retail druggists for sale to the consumer.

NPTEL
© IIT KGP 2019

We will see detail. Here the complainant was a medical company i.e. Dr. Miles medical company, an Indiana corporation which manufacturers and sells proprietary medicines. Most importantly, they were not holding any patents for these proprietary medicines rather they had trade secret protection which was again in the united states protected under legislations. So, it is a branch of intellectual property law which we saw in our earlier classes. They kept all the formulas and products as well as the process as trade secret; and they have packages, labels and trademarks.

So, there a bundle of intellectual property was protecting these particular medicines from trade secrets to the packages and labelling and also trademarks. They had trade extensively throughout the United States. Their practice was to sell the medicines to the jobbers, wholesalers, wholesale druggist and retail druggist and ultimately the medicines goes to the consumer and at all levels of trade the manufacturer used to fix the prices.

(Refer Slide Time: 05:31)



Trade secret

- The rights enjoyed by a patentee are derived from statutory grant under authority conferred by the Constitution,
- and are the reward received in exchange for advantages derived by the public after the period of protection has expired,
- and the rights of one not disclosing his **secret process** so as to secure a patent are outside of the policy of the patent laws,
- and must be determined by the legal principles applicable to the ownership of such process.
- Manufactured under **secret process – No Patents**

The slide features a light green background with a yellow-to-orange gradient at the bottom. On the left, there are two logos: the Indian Institute of Technology (IIT) logo and the NPTEL logo. On the right, there is a small video inset of a man in a pink shirt speaking. The text '© NPTEL IIT KGP/ROSD/2019' is visible at the bottom center.

When we look into the intellectual property protection the trade secrets are protected under the intellectual property legislations. But the question is whether there is a correlation between the intellectual property protection and controlling the market forces. Dr. Miles said that this is a proprietary medicine and different intellectual properties are owned by me. So, I have a right to protect the prices in the market.

So, you know that the processes were protected by the trade secrets. So, whether intellectual property protection grants any kind of rights to fix the prices. The answer is controversial. We have to look into whether intellectual property protection gives the patent owner or the copyright owner or the trade secret owner an absolute freedom to fix the prices, not only at one level but at every level.

(Refer Slide Time: 06:49)

The slide features a light green background with a darker green wave-like shape at the bottom. The title 'Restraint of trade' is centered at the top. Below it are two bullet points. At the bottom right, there is a video feed of a man in a pink shirt. The bottom left contains logos for IIT Bombay and NPTEL, with the text '© NPTEL KOPRIGSSOPL-2019'.

Restraint of trade

- A manufacturer of unpatented articles cannot, by rule or notice, in absence of statutory right, fix prices for future sales, even though the restriction be known to purchasers.
- Whatever rights the manufacturer may have in that respect must be by agreements that are lawful.

We will discuss this in detail. So, whether at any point of time this is a restraint of trade. So, here the same medical company manufactures non-patented articles also, but there is no statutory right on fixing prices for future sales or to put restrictions on the purchasers through a set of contracts.

The manufacturers set, fix conditions through a set of contracts from wholesale to retail and ultimately to the consumers. This is applicable not only in the case of the intellectual property protected medicines, but in the case of the non-patented medicines as well. So, the question is with regard to whether these agreements entered between these people are unlawful. Our point of discussion is that: these restrictive conditions put in the agreements are violative of any of the provisions of the Sherman Act. That is the question of our discussion, whether it is a restraint of trade.

(Refer Slide Time: 07:53)



The slide features a light green background with a darker green wave at the bottom. The title 'Restraint of trade' is centered at the top. Below it, two bullet points are listed. At the bottom left, there are three logos: the Indian Institute of Technology (IIT) logo, the NPTEL logo, and a small copyright notice '© IIT Bombay KGP/ROSOPL-2019'. On the bottom right, there is a small inset video of a man in a pink shirt.

Restraint of trade

- Agreements or combinations between dealers, having for their sole purpose the destruction of competition and fixing of prices, are injurious to the public interest and void;
- nor are they saved by advantages which the participants expect to derive from the enhanced price to the consumer.

© IIT Bombay KGP/ROSOPL-2019




There is an arrangement between the wholesalers, manufacturer, wholesalers and retailers through a set of agreements. So, the sole purpose is to control the entire market. The manufacturer fixes the prices. The question is whether these practice are injurious to public because if any kind of agreements put restraint of trade or are injurious to the public then they are void. So, if the public interest is hurt, these kind of agreements are held to be void.

And no other legislations can save such kind of agreements. So, the argument is that this is only to enhance the prices or only to control the entire market.

(Refer Slide Time: 08:53)

Per se rule

- Manufacturer to agree with its distributors to set the minimum price the distributor can charge for the manufacturers goods.
- Court applied the *per se rule* under S.1 of the Sherman Act and held the activities illegal.
- A vertical agreement between a manufacturer and distributors on resale price maintenance is *per se illegal*.



© NPTEL & IIT KGP 2019

The manufacturers along with the distributors agreed to fix the prices. MSPs are fixed. The court in this particular case applied the per se rule which is there in section 1 of the Sherman Act and held that these activities are illegal. The vertical agreements between the manufacturers, distributors and retailers, and ultimately reaching to the consumers, all the prices, were held to be per se illegal. The court has taken a very tough stand and held that these kind of agreements are not going to benefit the consumers rather they are going to benefit only the manufacturers and so are per se illegal.

(Refer Slide Time: 09:53)

Contract

- It was further alleged that, for the purpose of protecting "its trade sales and business" and of
- conserving "its goodwill and reputation," the complainant had established a method
- "of governing, regulating, and controlling the sale and marketing" of its remedies, which is thus described in the bill:
- "Contracts in writing were required to be executed by all jobbers and wholesale druggists to whom your orator sold its aforesaid remedies, medicines, and cures, of the following tenor and effect:"



© NPTEL & IIT KGP 2019

It was also further alleged that the purpose was of protecting trade, sales and business. This was one of the justification given by Dr. Miles. He said that it is to protect the sales and business and for conserving its goodwill and reputation. I am not able to understand how the reputation of a company is directly connected with the prices! Another argument was that all these were known to the defendants, through the agreement and they agreed earlier, they are part of this agreement. The defendant in this particular case co-operated with the plaintiff earlier and they knew the terms and conditions of the agreement.

Then second argument was; it is very necessary to regulate and control the sales and marketing of the company to protect the interest of the company. And thirdly the contracts are in writing, they are required to be executed by the jobbers or the retailers or the wholesalers and they knew these terms and conditions of these particular agreements. This was one of the argument.

The court looked into each and every argument. Every company wants to protect its trade and business, but not through exploiting the market, not through combinations, not through abuse of dominance. And every company wants to protect its goodwill and reputation but not by fixing prices and thirdly it is necessary to control the marketing. Yes, every company wants to control the market, but not by fixing the prices and the prices should be determined by the market forces. And if every company imposes restrictions on the wholesalers and retailers. So, the argument that the defendant knew the terms and conditions is not going to be sustainable.

(Refer Slide Time: 12:13)

The slide features a light green background with a white title 'Rival' at the top center. Below the title is a bulleted list of facts. In the bottom right corner, there is a small video inset of a man in a pink shirt. The bottom of the slide contains logos for IIT Bombay, NPTEL, and the text '© IIT Bombay KGP/PRO/SOPL, 2019'.

Rival

- The defendant is a Kentucky corporation conducting a wholesale drug business.
- The bill alleged that the defendant had formerly dealt with the complainant, and had full knowledge of all the facts relating to the trade in its medicines;
- that it had been requested, and refused, to enter into the wholesale contract required by the complainant;
- that in the City of Cincinnati, Ohio, where the defendant conducted a wholesale drug store,
- there were a large number of wholesale and retail druggists who had made contracts of the sort described, with the complainant, and kept its medicines on sale pursuant to the agreed terms and conditions.


The defendant i.e. the Kentucky corporation, the wholesale drug business, they were earlier into the business. So, they dealt with the complainant, they had full knowledge of the terms and conditions and they also trade in medicines. This argument is not going to be sustainable that they knew the terms and conditions; because even though they know the terms and conditions, it is still a restraint of trade and a violation of the Sherman Act.



You know that in pharmaceuticals, everybody knows that from the manufacturer to the consumer there are a lot of chains in the supply, there are lot of actors in the supply chain.

(Refer Slide Time: 12:51)

Combination

- It was charged that the defendant,
- "in combination and conspiracy with a number of wholesale and retail dealers in drugs and proprietary medicines, who have not entered into said wholesale and retail contracts"




  ©KDR/IT KGP/RSOPL, 2019



So, here there was a combination and a conspiracy with regard to the whole sellers, retailers and jobbers in the case of proprietary medicines. Even in the case of proprietary medicines, the rights are limited to the order of the intellectual property. Once the intellectual property is used to exploit the market, to violate any of the provisions of the competition law, the competition law will prevail over the intellectual property protection.

(Refer Slide Time: 13:33)

Mr. Justice Hughes


- The complainant, a manufacturer of proprietary medicines which are prepared in accordance with secret formulas, presents by its bill a system, carefully devised, by which it seeks to maintain certain prices fixed by it for all the sales of its products, both at wholesale and retail.
- Its purpose is to establish minimum prices at which sales shall be made by its vendees and by all subsequent purchasers who traffic in its remedies.



  ©KDR/IT KGP/RSOPL, 2019

And Mr. Justice Hughes in this particular case has taken a very strong stand. He said that there is no doubt that proprietary medicine are protected under the legislations. And they prepare these particular medicines under the trade secret formulas, it is protected under legislations and they can fix certain prices for retail or wholesale. But the purpose is to establish minimum prices at which sales shall be made by its vendors and by all subsequent purchasers who traffic in these medicines. So, the companies can only fix prices to that extent.

(Refer Slide Time: 14:15)



Contract restraints


- Its purpose is to establish minimum prices at which sales shall be made by its vendees and by all subsequent purchasers who traffic in its remedies.
- To accomplish this result it has adopted two forms of restrictive agreements limiting trade in the articles to those who become parties to one or the other.
- The one sort of contract, known as 'Consignment Contract Wholesale,' has been made with over four hundred jobbers and wholesale dealers,
- and the other described as 'Retail Agency Contract,' with twenty-five thousand retail dealers in the United States.

The slide features a green and yellow background. At the bottom, there are logos for IIT Bombay, NPTEL, and the text '© NPTEL KOPRIS001P1, 2019'. A small video inset of a man in a pink shirt is visible in the bottom right corner of the slide.

But can you put conditions on restraint of trade? The answer is no. No manufacturer can put conditions in the agreement in restraint of trade. So, these restrictive agreements, restrictive agreement conditions are void whether it is the consignment contracts or the retail contracts or the price fixing contracts, basically the retail agency contract.

So, the argument that there are 25,000 retailers are all over the United States, is not a justification to put unreasonable conditions. The conditions must satisfy the test of Sherman Act section 1 and 2, if any kind of restraint of trade provisions are put they would be a violation of the Sherman Act.

(Refer Slide Time: 15:07)



The slide features a light green background with a white title 'Remedy' at the top center. Below the title is a bulleted list of three conditions. At the bottom of the slide, there are three logos: the IIT Bombay logo on the left, the NPTEL logo in the center, and a small portrait of a man on the right. The text '© IIT Bombay 2019' is visible at the bottom right of the slide.

Remedy

- The complainant invokes the established doctrine that an actionable wrong is committed by one who maliciously interferes with a contract between two parties,
- and induces one of them to break that contract, to the injury of the other,
- and that, in the absence of an adequate remedy at law, equitable relief will be granted.

© IIT Bombay 2019

We are not going to discuss elaborately on the actionable wrong. The allegation by Dr. Miles that, the defendant has maliciously compelled other parties, other retailers and wholesalers to break the contract, that is not the question of our discussion. Our discussion is whether the intellectual property protection gives a complete freedom to the owner of the intellectual property to violate competition law?

The answer is that intellectual property protection has a limited role when it comes to the market forces.


(Refer Slide Time: 15:57)



The slide is titled "Patent law" and features three bullet points. The first bullet point states that the purpose of patent law is to stimulate invention by protecting inventors for a fixed time in the advantages that may be derived from exclusive manufacture, use, and sale. The second bullet point states that it is the reward stipulated for the advantages derived by the public for the exertions of the individual, and is intended as a stimulus to those exertions. The third bullet point states that the public yields nothing which it has not agreed to yield; it receives all which it has contracted to receive. The slide also includes logos for IIT Bombay, NPTEL, and a copyright notice for IIT Bombay 2019. A small inset video of a man speaking is visible in the bottom right corner of the slide.

Patent law


- The purpose of the patent law is to stimulate invention by protecting inventors for a fixed time in the advantages that may be derived from exclusive manufacture, use, and sale.
- 'It is the reward stipulated for the advantages derived by the public for the exertions of the individual, and is intended as a stimulus to those exertions. . . .
- The public yields nothing which it has not agreed to yield; it receives all which it has contracted to receive.

  © IIT Bombay 2019

The moment you exceed the intellectual property rights in the name of intellectual property protection you cannot do whatever you like to do in the market. For example, the patent law, the objective of the patent law is to stimulate innovation or to give an incentive to the innovator, but not to exploit the market.

There can be exclusive manufacturer, but if these exclusive manufacturer adopt unfair means and refuse to deal then, as we discussed in the last class, the essential facilities doctrine will come into play. So, the competition law is to take care of the market or competitive process has to continue in the market so that there will be welfare in the market. And if the public is not going to yield any benefit, if they are not going to get any kind of benefits because of the practices of the company then definitely it is going to attract the provisions of the Sherman Act.

(Refer Slide Time: 17:03)



The slide features a light green background with a white title 'Restrictive' at the top center. Below the title is a bulleted list of four points. At the bottom of the slide, there are three logos: the Indian Institute of Technology (IIT) logo on the left, the NPTEL logo in the center, and a small portrait of a man on the right. The text 'ENDRIT KGPINSDIPL-2019' is visible at the bottom right of the slide.

Restrictive

- The full benefit of the discovery, after its enjoyment by the discoverer for fourteen years, is preserved; and for his exclusive enjoyment of it during that time the public faith is pledged. . .
- The great object and intention of the act is to secure to the public the advantages to be derived from the discoveries of individuals,
- and the means it employs are the compensation made to those individuals for the time and labor devoted to these discoveries,
- by the exclusive right to make, use, and sell the things discovered for a limited time.'

NPTEL ENDRIT KGPINSDIPL-2019

So, whether a condition in the contract is a restrictive practice or not, we have to look in from the purview of intellectual property as well as the competition law. And there can be an exclusive agreement according to the intellectual property law because you have a monopoly for a limited period of time, but that does not mean that you refuse to deal.

So, the refusal to deal i.e. to be dealt under the competition law, competition law will come into play and will look into the details of why you refused, whether you are charging enormous royalties, whether you are fixing the prices, whether you are going to be making cartels. So, all these ingredients are to be checked under the competition law.

(Refer Slide Time: 17:51)

NEW DOJ/FTC Guidelines

- In January 12, 2017, the U.S. Department of Justice and the Federal Trade Commission released updated Antitrust Guidelines for the Licensing of Intellectual Property.

1. “The Agencies apply the same antitrust analysis to conduct involving intellectual property as to conduct involving other forms of property, taking into account the specific characteristics of a particular property right”;
2. “the Agencies **do not presume** that intellectual property creates market power”; and
3. “the Agencies recognize that intellectual property licensing allows firms to combine complementary factors of production and is generally pro-competitive.”

The slide features a light green background with a yellow-to-orange gradient at the bottom. On the left, there are two logos: the Indian Institute of Technology (IIT) logo and the NPTEL logo. On the right, there is a small video inset showing a man in a pink shirt speaking. The text '© IIT KGP 2019' is visible at the bottom right of the slide.

And if we look into Dr. Miles it is very clear. The court has, remember this particular case was in 1911, very clearly applied the doctrine of per se rule and they said we are not even going to look into the other doctrines, the opposite doctrines.


The next case we will look into is in 2007. In 2017, the Department of Justice and the Federal Trade Commission has issued new guidelines by looking into the new jurisprudence. The new guidelines of 2017 has accepted these particular principles and the first principle says that: “the agencies apply the same antitrust analysis to conduct involving intellectual property as to conduct involving other forms of property taking into account the specific characteristics of a particular property right”.

So, they have to consider what kind of intellectual property protection is available, to what extent it is available to the owner. But at the same time “the antitrust agencies do not presume that intellectual property creates market power”. So, they have changed their philosophy of the competition issue, because Dr. Miles was overruled in *Leegin* case. So, we are going to see that particular case.

Thirdly, “the agencies recognise that intellectual property licensing allows firms to combine complementary factors or production”. Yesterday we talked about the complementary technologies and supplementary technologies and the agencies will

consider it as pro-competitive. So, the per se rule is not going to be applicable. So, the rule of reason is going to be applied from 2017 in the cases, so the shift has happened.

(Refer Slide Time: 20:03)



NEW DOJ/FTC Guidelines

- A shift in case law occurred in 2007, when the Supreme Court decided *Leegin Creative Leather Products, Inc. v. PSKS, Inc.*, 551 U.S. 877 (2007).
- In *Leegin*, the Court concluded that RPM agreements should be evaluated under the rule of reason and are not *per se* illegal,
- overruling the 1911 decision in *Dr. Miles Med. Co. v. John D. Park & Sons Co.*, 220 U.S. 373 (1911),
- holding that the agreements were *per se* illegal.
- To reflect the new caselaw, the Guidelines state that RPM agreements will be analyzed on a case-by-case basis, weighing the competitive benefits against the potential harms of RPM agreements.

The slide features a green background with a white text box. At the bottom, there is a yellow banner with the NPTEL logo and a small video inset of a man in a pink shirt speaking.

So, we talked about how in *Dr. Miles*, the court said that the per se rule will be applicable, fixing vertical agreements are per se illegal. But, in 2007 another case came before the supreme court of the united states i.e. *Leegin Creative Leather Products Inc. verses PSKS, Inc.*. Almost similar circumstances, similar facts. In *Leegin* the court reconsidered *Dr. Miles* case regarding resale price maintenance.

Whether the resale price maintenance is per se illegal. This question was evaluated. If you apply *Dr. Miles* principle then you need not re-evaluate, so blindly you can say that if you apply *Dr. Miles*, resale price maintenance are per se illegal. But, in this particular case the court again looked into and evaluated very thoroughly whether these are per se illegal, resale price maintenance are illegal at the vertical level? Whether it has an anti-competitive effect or pro-competitive effects. So we will discuss this particular case.

Thank you.